PetMeds delays Q4 and fiscal 2025 earnings release

Published 10/06/2025, 21:14
PetMeds delays Q4 and fiscal 2025 earnings release

DELRAY BEACH, Fla. - PetMed Express, Inc. (NASDAQ:PETS), which operates under the PetMeds brand and owns PetCareRx, announced Tuesday it is postponing the release of its fourth quarter and fiscal year 2025 financial results. The company, currently trading at $4.19 and showing a strong 4.3% return over the past week, maintains a market capitalization of $86.5 million.

The company stated it needs additional time to complete its year-end audit process. The earnings release and conference call, originally scheduled for June 10, 2025, will now take place by June 16, 2025, according to the company’s statement.

PetMed Express, founded in 1996, operates as an online pet pharmacy through its PetMeds.com and PetCareRx.com websites, offering prescription and over-the-counter medications along with other pet products.

The company indicated in its press release statement that it plans to file its Annual Report on Form 10-K within the same timeframe as the rescheduled earnings announcement.

PetMed Express provides medications, food products, and supplies for dogs, cats, and horses through its digital platforms, according to the company.

In other recent news, PetMed Express announced a strategic partnership with Dutch, a virtual veterinary care provider. This collaboration aims to address the nationwide vet shortage by integrating Dutch’s telemedicine services with PetMed Express’s medication offerings, making pet healthcare more accessible. Additionally, Morgan Stanley has adjusted its outlook on PetMed Express, reducing the price target from $3.50 to $3.20 while maintaining an Underweight rating on the stock. The firm acknowledges the company’s strong market position but highlights challenges due to increasing competition.

PetMed Express has also made changes to its Board of Directors, appointing Peter Batushansky, a seasoned executive with extensive experience in retail and pet healthcare. This appointment follows the announcement of Dr. Gian Fulgoni’s upcoming retirement from the board. The company is undergoing a transformation with several leadership changes, including the appointment of Sandra Campos as CEO and President. These developments reflect PetMed Express’s commitment to expanding its online pet pharmacy business and enhancing its position in the pet wellness ecosystem.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.